Practice-Changing Research Webinar

Dr Hertzel Gerstein is an Endocrinologist and Professor at McMaster University and Hamilton Health Sciences in Canada. His research firmly established international long-term diabetes-focused outcomes RCTs as the norm to support Evidence-Based Diabetes Care. Trials he designed and led have randomized more than 90,000 people with either diabetes or prediabetes, and have studied and identified clinically important, life-saving diabetes therapies.

These plus many biomarker studies, editorials, and epidemiologic analyses have been published in > 600 papers. His papers are often cited with an h-index is 104. His awards include the 2012 Canadian Diabetes Association’s Lifetime Achievement Award and the 2022 American Diabetes Association’s Outstanding Achievement in Clinical Diabetes Research Award.

Disclosures

Consulting – Novo Nordisk, Zealand, Shionogi

Speaker – Lilly, Novo Nordisk, AstraZeneca, Zuellig, Abbott, Jiangsu-Hansen

Grants to my institution for research or CME – Novo Nordisk, Sanofi, Abbott, Eli Lilly, Boehringer Ingelheim

Dr. Calvin Ke is an Assistant Professor in the Department of Medicine and Institute of Health Policy, Management and Evaluation, University of Toronto, a clinician scientist at the Toronto General Hospital Research Institute, an adjunct scientist at ICES, and a staff endocrinologist at the Toronto General Hospital, University Health Network in Toronto, Canada. He directs the Epidemiologic and Applied Research Lab in Young‑Onset Diabetes​ (EARLY Diabetes, earlydiabetes.ca), and leads the Health Services and Quality of Care Working Group of the Novo Nordisk Network for Healthy Populations at the University of Toronto. He received his Doctor of Medicine from the University of Toronto. He completed his residency training in Internal Medicine at the University of British Columbia and in Endocrinology and Metabolism at the University of Toronto. He completed his PhD in clinical epidemiology and global health as a Global Scholar at the Institute of Health Policy, Management and Evaluation, University of Toronto. His research interests include the management and outcomes of type 2 diabetes, with a focus on young-onset type 2 diabetes and on Chinese and South Asian populations. He has conducted diabetes research internationally across Canada, China, India, and Guyana. His research publications have appeared in high-impact, peer-reviewed journals such as JAMA, Annals of Internal Medicine, Diabetes Care, The Lancet Global Health, PLoS Medicine, and Nature Reviews Endocrinology. He previously served as an Honorary Visiting Scholar at The Chinese University of Hong Kong, and has received multiple awards including the Canadian Society of Endocrinology and Metabolism Dr. Fernand Labrie Fellowship Research Award, the Queen Elizabeth Advanced Scholars Award, and the South Asian Network Supporting Awareness and Research Burgundy Young Investigator Award. He serves as Associate Editor of Primary Care Diabetes, Section Editor of Current Diabetes Reports, National Consultant Editor of the Canadian Journal of Diabetes, and as a member of the International Diabetes Federation Atlas Committee and the NCD Risk Factor Collaboration. As a second-generation Chinese Canadian with roots in Hong Kong, he engages closely with ethnically diverse communities in his research and clinical work.

Disclosures

No relationship with a for-profit and/or a not-for-profit organization to disclose.

Hertzel Gerstein Disclosures

Consulting – Novo Nordisk, Zealand, Shionogi
Speaker – Lilly, Novo Nordisk, AstraZeneca, Zuellig, Abbott, Jiangsu-Hansen
Grants to my institution for research or CME – Novo Nordisk, Sanofi, Abbott, Eli Lilly, Boehringer Ingelheim

Calvin Ke Disclosures

No relationship with a for-profit and/or a not-for-profit organization to disclose.

Anna Sawka Disclosures